Developing the Catheter Business into a Second Core Product Group
First written in FY2016. 9 of 19 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2026.
The whole theme swung hardest in 2026: 1 of 7 companies on the "Worse" side.
1 other company's latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「In the cerebrovascular field, we developed SAYA86, a guiding catheter for radial access.」
We developed the SAYA86 guiding catheter for cerebrovascular applications, expanding our catheter product portfolio. - FY2025AdvancedAnnual report
「Branchor X, a guiding catheter for cerebrovascular treatment, has received FDA approval, and preparations are under way for its sale in the United States.」
Branchor X received FDA approval in the catheter business, and preparations for U.S. sales are under way. - FY2025-H1RestatedAnnual report
「Overseas markets increased in both the cardiovascular and non-cardiovascular fields. Although the cardiovascular business included concentrated, one-time orders covering the full year from a distributor in Eastern Europe in the European region during the previous first-quarter consolidated accounting period, revenue performed extremely well across all regions, led by PCI guidewires and penetration catheters.」
The company said that cardiovascular products, led by PCI guidewires and penetration catheters, performed well across all regions. No specific milestones, such as the launch of new products, were indicated. - FY2023AdvancedAnnual report
「In the catheter business, we developed FUBUKI XF for use in cerebrovascular treatment.」
The company developed FUBUKI XF, a catheter for cerebrovascular treatment, giving concrete form to the expansion of its core catheter product lineup. - FY2023-Q1AdvancedAnnual report
「As measures toward achieving this, during the three months ended the first quarter, we entered into ① a basic agreement for the exclusive distribution in Japan of Penumbra Inc.’s (U.S.) thrombus aspiration devices for peripheral vessels, ② an exclusive distribution agreement in China for DK MEDTECH (Suzhou) Co., Ltd.’s “DK Score coronary scoring balloon dilatation catheter,” and ③ issued the Group’s first “Integrated Report 2022.”」
The company entered into an exclusive distribution agreement in China for the DK Score coronary scoring balloon dilation catheter, concretely expanding its range of catheter products. - FY2021RestatedAnnual report
「In addition, to establish second and third core products following PTCA guidewires, we will further strengthen and expand our catheter product lineup in the cardiovascular field.」
The company continues to pursue its policy of developing catheter product groups into its second and third core products. - FY2020RestatedAnnual report
「As measures to achieve this, during the current consolidated fiscal year we began selling the new nickel-titanium hybrid PTCA guidewire MINAMO (ミナモ) and the neurovascular balloon guide catheter Branchor (ブランカー).」
The launch of sales of Branchor, a new product in the catheter business, is being reaffirmed as an initiative to develop the second and third core product groups. - FY2020-Q3RestatedAnnual report
「As measures to achieve this, during the nine months ended 31 December of the current fiscal year we began selling the new nickel-titanium hybrid PTCA guidewire MINAMO (ミナモ) and the neurovascular balloon guide catheter Branchor (ブランカー).」
The launch of Branchor sales, a new product in the catheter business, is being reaffirmed as an initiative to develop the second and third core product groups. - FY2020-Q2AdvancedAnnual report
「We began sales of MINAMO, a nickel-titanium hybrid PTCA guidewire, and Branchor, a balloon-tipped guiding catheter for cerebrovascular procedures, as new products.」
The company began sales of Branchor, a new balloon-tipped guiding catheter for cerebrovascular procedures in the catheter business. - FY2020-Q1AdvancedAnnual report
「Launch of limited sales of MINAMO, a nickel-titanium hybrid PTCA guidewire, and Branchor, a balloon-tipped guiding catheter for cerebral procedures, as new products」
The company began limited sales of Branchor, a new balloon-tipped guiding catheter for cerebral procedures in the catheter business. - FY2019RestatedAnnual report
「In addition, to establish second and third core products following PTCA guidewires, we will further strengthen and expand our catheter product lineup in the cardiovascular field, including PTCA balloon catheters, PTCA guiding catheters and penetration catheters, by combining the stainless-steel processing and resin processing technologies held by our group.」
The company continues to pursue its policy of developing the catheter business into its second and third core product groups. - FY2018RaisedAnnual report
「In addition, to establish second and third core products following PTCA guidewires, we will further strengthen and expand our catheter product lineup in the cardiovascular field, including PTCA balloon catheters, PTCA guiding catheters and penetration catheters, by combining the stainless-steel processing and resin processing technologies held by our group.」
The company has broadened its focus from the former “second core product” to “second and third core products,” presenting a broader policy for developing its catheter product groups. - FY2018-Q2RestatedAnnual report
「Sales of PTCA guidewires and the penetration catheter SASUKE (サスケ) continued to grow. Sales of the new PTCA balloon catheter NC kamui (エヌシーカムイ) also increased as it gained market share, resulting in strong performance.」
The company is reaffirming increased sales in the catheter business, which it aims to develop into its second core product group, driven by sales growth of SASUKE and market-share gains for NC kamui. - FY2018-Q1AdvancedAnnual report
「Sales of PTCA guidewires and the penetration catheter SASUKE (サスケ) continued to grow. Sales of the new PTCA balloon catheter NC-kamui (エヌシーカムイ) also increased as it gained market share, resulting in strong performance.」
Sales of NC-kamui, a new PTCA balloon catheter, increased in the catheter business, which the company aims to develop into its second core product group, due to market-share gains. - FY2017RestatedAnnual report
「Meanwhile, to establish a second core product following PTCA guidewires, we will further strengthen and expand our catheter product lineup in the cardiovascular field, including PTCA balloon catheters, PTCA guiding catheters and penetration catheters, by combining the stainless-steel processing and resin processing technologies held by our group.」
The company continues to pursue its policy of developing the catheter business into the second core product group following PTCA guidewires. - FY2017-Q3AdvancedAnnual report
「In overseas markets, we began rolling out product groups already sold and highly regarded in Japan. In Europe, we began sales of Caravel and Corsair Pro, cardiovascular penetration catheters, and Hyperion, a PTCA guiding catheter, while in the United States we began sales of Corsair Pro, a cardiovascular penetration catheter, among other products.」
The company advanced the rollout of Caravel, Corsair Pro and Hyperion in Europe and the United States as part of its effort to develop the catheter business into the second core product group. - FY2017-Q2RestatedAnnual report
「In overseas markets, we began sales in Europe of Caravel, a cardiovascular penetration catheter, and Hyperion, a PTCA guiding catheter, both of which are already sold and highly regarded in Japan.」
As part of the effort to develop the catheter business into the second core product group, the company is reiterating the launch of Caravel and Hyperion sales in Europe. - FY2017-Q1AdvancedAnnual report
「In overseas markets, we began limited sales in Europe of Caravel, a cardiovascular penetration catheter, and Hyperion, a PTCA guiding catheter, both of which are already sold and highly regarded in Japan.」
The company began limited sales in Europe in the catheter business, which it aims to develop into a product group following PTCA guidewires. - FY2016First statedAnnual report
「Meanwhile, to establish a second core product following PTCA guidewires, we will further strengthen and expand our catheter product lineup in the cardiovascular field, including PTCA balloon catheters and PTCA guiding catheters, by combining the stainless-steel processing and resin processing technologies held by our group.」
The company aims to establish a second core product, using the combination of stainless-steel processing and resin processing technologies as the means to achieve this.